Literature DB >> 22445675

Antibody-cytokine fusion proteins.

Roland E Kontermann1.   

Abstract

Cytokines are key players in stimulating and regulating immune responses in physiological and pathophysiological processes. Various cytokines have been approved for therapy of cancer and other diseases and many more are under development. However, therapeutic efficacy is often hampered by severe side effects and poor pharmacokinetic properties. Fusion of cytokines to antibodies or antibody fragments allows for a targeted delivery and should, therefore, improve efficacy and pharmacokinetics. This review provides a comprehensive summary of the developments in the field of targeted cytokine delivery by genetic engineering of antibody-cytokine fusion proteins.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22445675     DOI： 10.1016/j.abb.2012.03.001

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN： 0003-9861            Impact factor:   4.013


  32 in total

1.  Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding.

Authors:  Avi Robinson-Mosher; Jan-Hung Chen; Jeffrey Way; Pamela A Silver
Journal:  Biophys J       Date:  2014-11-18       Impact factor: 4.033

2.  A targeted IL-15 fusion protein with potent anti-tumor activity.

Authors:  Siqi Chen; Qiang Huang; Jiayu Liu; Jieyu Xing; Ning Zhang; Yawei Liu; Zhong Wang; Qing Li
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

3.  Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.

Authors:  Sina Fellermeier; Nadine Beha; Jan-Erik Meyer; Sarah Ring; Stefan Bader; Roland E Kontermann; Dafne Müller
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

4.  A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets.

Authors:  John J Rhoden; Gregory L Dyas; Victor J Wroblewski
Journal:  J Biol Chem       Date:  2016-03-28       Impact factor: 5.157

Review 5.  Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.

Authors:  Christian Fercher; Sahar Keshvari; Michael A McGuckin; Ross T Barnard
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-19

6.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

Review 7.  Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.

Authors:  Patricia A Young; Sherie L Morrison; John M Timmerman
Journal:  Semin Oncol       Date:  2014-08-12       Impact factor: 4.929

8.  IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.

Authors:  Xuefeng Wang; Xin Zhao; Chao Feng; Aliyah Weinstein; Rui Xia; Wen Wen; Quansheng Lv; Shuting Zuo; Peijun Tang; Xi Yang; Xiaojuan Chen; Hongrui Wang; Shayang Zang; Lindsay Stollings; Timothy L Denning; Jingting Jiang; Jie Fan; Guangbo Zhang; Xueguang Zhang; Yibei Zhu; Walter Storkus; Binfeng Lu
Journal:  Cancer Cell       Date:  2015-08-27       Impact factor: 31.743

9.  An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Authors:  Martin Siegemund; Oliver Seifert; Maria Zarani; Tamara Džinić; Valentino De Leo; Doris Göttsch; Sabine Münkel; Meike Hutt; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2016-04-11       Impact factor: 5.857

Review 10.  Immunostimulatory biomaterials to boost tumor immunogenicity.

Authors:  Oluwaseyi T Shofolawe-Bakare; Larry D Stokes; Mehjabeen Hossain; Adam E Smith; Thomas A Werfel
Journal:  Biomater Sci       Date:  2020-09-02       Impact factor: 6.843
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.